nHale, A New Ventilation Device for the Treatment of COVID-19 to Be Distributed Nationwide

nHale, is a non-invasive respiratory support device authorized for the treatment of COVID-19 patients in the hospital, spaces converted for the treatment of COVID-19 patients, and in the private home. Solutions in Critical Care (SCC) has partnered with Nanotronics Health, LLC, to distribute nHale.

The new agreement allows for Nanotronics Health, LLC, to work with a leading distributor to deliver affordable and easy-to-use respiratory support devices for hospital systems within the United States that are experiencing surging COVID-19 patients.

Non-invasive ventilation is critical for COVID-19 patient care in the hospital and beyond. To meet this need, Nanotronics Health, LLC, leveraged Nanotronics’ deep in-house expertise, incorporating advanced AI, Intelligent Factory Control (IFC) and sophisticated engineering to conceive, design and manufacture nHale™ in under 90 days. The incorporation of IFC enables optimized manufacturing efficiency and the ability to scale production quickly while also avoiding a complex global supply chain. The quick production allows for healthcare providers to rely on Nanotronics Health, LLC, for cost-effective respiratory support devices for the treatment of COVID-19 patients.

“We are pleased to partner with an established distributor who understands the need to deliver accessible devices to patients and healthcare professionals when they need it,” said Julie Orlando, President of Nanotronics Health, LLC. “As hospitals continue to be strained throughout the country, it is our hope that we can provide a solution to both ease that strain while also providing reliable at-home support.”

SCC is a national network of well-established specialty distribution partners in the medical device industry. With eight distribution partners across the U.S., SCC offers medical device manufacturers a national strength with a local sales presence to grow their product line. “We intentionally choose products and companies that will make an impact and nHale™ is a much-needed disruption in the single bi-level system space,” says John Marmo, President of Solutions in Critical Care. “We look forward to bringing this and other critical care products to the forefront through our partnership with Nanotronics Health.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version